Cyclobenzaprine Raises ROS Levels in < i > Leishmania infantum < /i > and Reduces Parasite Burden in Infected Mice

Conclusion/SignificanceTo the best of our knowledge, this study is the first report of thein vivo antileishmanial activity of the FDA-approved drug CBP. Modulation of immune response and induction of oxidative stress in parasite seem to contribute to this efficacy.

http://feeds.plos.org/~r/plosntds/NewArticles/~3/NGsptpxl_cw/article

Source: PLoS Neglected Tropical Diseases - January 2, 2017 Category: Tropical Medicine Authors: Ed ézio Ferreira Cunha-Júnior Source Type: research